Hiba Abouassi, MD
Endocrinology, Diabetes & Metabolism · Durham, NCNPI 1063617470
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $757 of the $1,032 with a category attached, or 73.4%. Every reported general payment came from a single manufacturer, Novo Nordisk AS. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in NC, where the typical reported total is $1,143.
Across 4 payments — averaging $257.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$1K
Across 680 payments — averaging $744.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$506K
- Novo Nordisk$25
What the payments were for
- Travel & lodging$75773%
- Food & beverage$27527%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 4 | $1,032 |
How this compares
$1,032 in reported general payments places this provider in the 45th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 116 | $202,370 |
| TrulicityDulaglutide | 84 | $116,347 |
| MounjaroTirzepatide | 61 | $83,440 |
| Tresiba Flextouch U-100Insulin Degludec | 56 | $30,134 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $28,726 |
| JardianceEmpagliflozin | 28 | $27,436 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 15 | $22,511 |
| RybelsusSemaglutide | 20 | $21,600 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 11 | $21,359 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $20,498 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $19,974 |
| Novolog FlexpenInsulin Aspart | 51 | $15,388 |
| Humalog Kwikpen U-100Insulin Lispro | 60 | $15,220 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 131 | $12,609 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 74 | $11,994 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Durham
- Jennifer GreenDurham$439K
- Todd FriezeDurham$421K
- David D AlessioDurham$212K
- Thomas WeberDurham$16K
- Leena ShahlaDurham$14K
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
- Michael FavoritoWilmington$723K
- Stephen SouthGreensboro$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.